Brookline Capital Management Analyst Recommendations & Stock Picks

This page lists the most recent publicly-reported stock recommendations and ratings issued by analysts at Brookline Capital Management. These ratings and price targets were collected from pubilc media reports and are believed to be accurate, but cannot be verified with 100% certainty. MarketBeat and its parent company are in no way affiliated with or endorsed by Brookline Capital Management.

Company	Date	Action	Brokerage	Rating	Price Target	Impact on Price	Actions
BCDA Biocardia	11/26/2019	Reiterated by	Brookline Capital Management	Buy		Low
BCDA BioCardia	11/26/2019	Initiated by	Brookline Capital Management	Buy	$22.00	Low
MDNA Medicenna Therapeutics	11/19/2019	Reiterated by	Brookline Capital Management	Buy	C$4.00	N/A
BCEL Atreca	8/20/2019	Reiterated by	Brookline Capital Management	Buy		High
SCYX SCYNEXIS	8/19/2019	Reiterated by	Brookline Capital Management	Buy		High
VXRT Vaxart	8/15/2019	Initiated by	Brookline Capital Management	Buy	$6.00	Low
CLSN Celsion	7/25/2019	Reiterated by	Brookline Capital Management	Buy		Medium
CHMA Chiasma	7/24/2019	Reiterated by	Brookline Capital Management	Buy		Low
PGNX Progenics Pharmaceuticals	7/29/2019	Initiated by	Brookline Capital Management	Buy	$10.00	Low
VERU Veru	7/29/2019	Initiated by	Brookline Capital Management	Buy	$12.00	High
HTBX Heat Biologics	7/29/2019	Initiated by	Brookline Capital Management	Buy	$8.00 -> $8.00	High
CLRB Cellectar Biosciences	7/29/2019	Initiated by	Brookline Capital Management	Buy	$6.00 -> $6.00	High
ARCT Arcturus Therapeutics	7/24/2019	Reiterated by	Brookline Capital Management	Buy		High
QBIO Q BioMed	5/10/2019	Reiterated by	Brookline Capital Management	Buy		Low
CHMA Chiasma	2/6/2019	Reiterated by	Brookline Capital Management	Buy		Low
SCYX SCYNEXIS	1/4/2019	Reiterated by	Brookline Capital Management	Buy		High
REXN Rexahn Pharmaceuticals	11/27/2018	Reiterated by	Brookline Capital Management	Buy		N/A
CLSN Celsion	11/20/2018	Reiterated by	Brookline Capital Management	Buy		Medium
CLRB Cellectar Biosciences	11/20/2018	Reiterated by	Brookline Capital Management	Buy		Low
ARCT Arcturus Therapeutics	9/27/2018	Reiterated by	Brookline Capital Management	Buy		Low
HTBX Heat Biologics	8/1/2018	Reiterated by	Brookline Capital Management	Buy		Low
HSGX Histogenics	8/1/2018	Reiterated by	Brookline Capital Management	Buy		Medium
TNXP Tonix Pharmaceuticals	7/27/2018	Downgraded by	Brookline Capital Management	Buy -> Hold		Low
PRTO Proteon Therapeutics	6/26/2018	Reiterated by	Brookline Capital Management	Buy		Medium
TNXP Tonix Pharmaceuticals	5/1/2018	Reiterated by	Brookline Capital Management	Buy		Low

MarketBeat Community Rating for Brookline Capital Management

Community Ranking:		2.1 out of 5 ( )
Outperform Votes:		17,642 (Vote Outperform)
Underperform Votes:		24,451 (Vote Underperform)
Total Votes:		42,093